Shares of Intersect ENT XENT remained unaffected after the company reported Q1 results.
Quarterly Results
Earnings per share rose 5.56% year over year to ($0.51), which missed the estimate of ($0.42).
Revenue of $24,328,000 higher by 22.71% year over year, which beat the estimate of $23,540,000.
Looking Ahead
The upcoming fiscal year's revenue expected to be between $117,000,000 and $121,000,000.
Details Of The Call
Date: May 10, 2021
Time: 08:30 AM
ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=sz7oCRPv
Technicals
Company's 52-week high was at $26.98
Company's 52-week low was at $10.84
Price action over last quarter: down 1.87%
Company Overview
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.